Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zegocractin - CalciMedica

Next Previous
Drug Profile

Zegocractin - CalciMedica

Alternative Names: Auxora; CM-4620; CM4620-IE

Latest Information Update: 21 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CalciMedica
  • Class Anti-inflammatories; Antivirals; Benzamides; Chlorobenzenes; Dioxoles; Fluorobenzenes; Pyrazines; Small molecules; Urologics
  • Mechanism of Action ORAI1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatitis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III COVID-19 pneumonia
  • Phase II Acute kidney injury; Pancreatitis; SARS-CoV-2 acute respiratory disease; Systemic inflammatory response syndrome
  • Preclinical Inflammatory bowel diseases; Renal failure; Respiratory distress syndrome

Most Recent Events

  • 12 Nov 2025 CalciMedica has constructive engagement with the FDA regarding the design of a pivotal trial in AP. The Company expects to finalize the pivotal trial design in the first half of 2026
  • 10 Nov 2025 Pharmacodynamics data from a preclinical study in Acute kidney injury released by CalciMedica
  • 12 Aug 2025 CalciMedica plans to meet with USFDA for Acute pancreatitis in second half of 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top